# National Center for Tumor Diseases

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/national-center-for-tumor-diseases/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 79.5 |
| Citations | 1,761,514 |
| City | Heidelberg |
| Country | DE |
| Description | National Center for Tumor Diseases is a research organisation in Heidelberg, DE. OpenAlex records 12,680 works and 1,761,514 citations for it. 2,508 researchers list it as their most recent affiliation. |
| Homepage | https://www.nct-heidelberg.de |
| OpenAlex ID | https://openalex.org/I4210111460 |
| Researchers | 2,508 |
| ROR ID | https://ror.org/01txwsw02 |
| Type | funder |
| Works | 12,680 |

## University papers

- [Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis](https://scholariq.org/papers/analysis-of-flt3-activating-mutations-in-979-patients-with-acute-myelogenous/)
- [Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial](https://scholariq.org/papers/azacitidine-for-treatment-of-imminent-relapse-in-mds-or-aml-patients-after/)
- [Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents](https://scholariq.org/papers/randomized-phase-iii-study-of-lenalidomide-versus-placebo-in-rbc-transfusion/)
- [Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms](https://scholariq.org/papers/phase-i-first-in-human-dose-escalation-study-of-the-oral-sf3b1-modulator-h3b/)
- [A novel prognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial](https://scholariq.org/papers/a-novel-prognostic-model-in-elderly-patients-with-acute-myeloid-leukemia-results/)

## University top topics

Showing 8 of 25.

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer survivorship and care](https://scholariq.org/topics/cancer-survivorship-and-care/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.